Zobrazeno 1 - 1
of 1
pro vyhledávání: '"621"'
Autor:
Anthony R. Mato, David F. Claxton, Bruce D. Cheson, Jeffrey J. Pu, Clive S. Zent, Molly Fanning, Colleen Timlin, Lauren E. Strelec, Krista Isaack, Allan-Louie Cruz, Paul M. Barr, Nicole Lamanna, David L. Porter, Catherine Daniel, Daniel J. Landsburg, Spencer Henick Bachow, Chaitra S. Ujjani, Pavel Kiselev, Melissa Yacur, Christina Howlett, Allison M. Winter, Danielle M. Brander, Kaitlin Kennard, Chadi Nabhan, Stephen J. Schuster, Brian T. Hill, Alan P Skarbnik, Sunita D. Nasta
Publikováno v:
Blood. 128:3222-3222
Introduction: Ibrutinib (Ibr) is a kinase inhibitor (KI) indicated for treating CLL. Clinical trials that led to its approval showed that its unique side effects differ from traditional chemotherapy toxicities. We previously reported (Mato et al, ASH